Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Practical Applications of a Nausea and Vomiting Model in the Clinical Development of Additional Doses of Dulaglutide
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-10-19
DOI
10.1002/jcph.2373
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making
- (2022) Rajanikanth Madabushi et al. PHARMACEUTICAL RESEARCH
- Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care
- (2022) Elpiniki Rentzeperi et al. Journal of Personalized Medicine
- Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
- (2021) Juan P. Frias et al. DIABETES CARE
- 642-P: A Model-Based Evaluation of Nausea and Vomiting Events for Additional Doses of Dulaglutide in Existing and Dulaglutide-Naïve Patients with Type 2 Diabetes
- (2021) LAI-SAN THAM et al. DIABETES
- Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
- (2021) Sean Wharton et al. DIABETES OBESITY & METABOLISM
- Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
- (2021) Joanna Van et al. Diabetes Therapy
- Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice
- (2021) Sean Wharton et al. POSTGRADUATE MEDICINE
- Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine
- (2020) Anna H.-X. P. Chan Kwong et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study
- (2019) Sieta T. Vries et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy and Safety of an Expanded Dulaglutide Dose Range: A Phase 2, Placebo‐controlled Trial in Patients with Type 2 Diabetes on Metformin
- (2019) Juan P. Frias et al. DIABETES OBESITY & METABOLISM
- GLP-1 and weight loss: unraveling the diverse neural circuitry
- (2016) Scott E. Kanoski et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials
- (2015) Jeanne S. Geiser et al. CLINICAL PHARMACOKINETICS
- A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
- (2015) Michael A. Nauck et al. DIABETES CARE
- Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
- (2015) Feng Sun et al. Diabetes Technology & Therapeutics
- Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
- (2014) Carol Wysham et al. DIABETES CARE
- Dulaglutide: First Global Approval
- (2014) Mark Sanford DRUGS
- Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study
- (2014) Richard E Pratley et al. Lancet Diabetes & Endocrinology
- Performance of Three Estimation Methods in Repeated Time-to-Event Modeling
- (2011) Kristin E. Karlsson et al. AAPS Journal
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review
- (2011) Vanita R. Aroda et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models
- (2011) Maria C. Kjellsson et al. PHARMACEUTICAL RESEARCH
- Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients
- (2010) Roberto Bizzotto et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis
- (2009) B D Lacroix et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Modelling overdispersion and Markovian features in count data
- (2009) Iñaki F. Trocóniz et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started